Figure
Microarray Analysis
This high-throughput approach provides a comprehensive view of gene activity, allowing researchers to investigate complex biological processes and identify disease-related patterns.
By analyzing the expression profiles of multiple genes, Microarray Analysis facilitates the discovery of novel genetic markers, the elucidation of regulatory networks, and the development of personalized diagnostic and therapeutic strategies.
However, the effective application of this technology requires carefull selection of appropriate protocols and analysis methods to ensure reproducibility and accuracy of the results.
PubCompare.ai, an AI-driven platform, optimizes Microarray Analaysis by helping users find the best protocols from literature, pre-prints, and patents.
Leveraging AI-driven comparisons, PubCompare.ai enhances reproducibility and research accuracy, ensuring your Microarray Analysis is precise and reliable.
Most cited protocols related to «Microarray Analysis»
Figure
The second program ‘identifies’ statistically significantly enriched pathways and diseases by comparing results from the first program against the background (usually genes from the whole genome, or all probe sets on a microarray). Users can define their own background distribution in KOBAS 2.0 (for example, result from the first program to ‘annotate’ all probe sets on a microarray). If users do not upload a background file, KOBAS 2.0 uses the genes from whole genome as the default background distribution. Here, we consider only pathways and diseases for which there are at least two genes mapped in the input. Users can choose to perform statistical test using one of the following four methods: binomial test, chi-square test, Fisher's exact test and hypergeometric test, and perform FDR correction. The purpose of performing FDR correction is to reduce the Type-1 errors. When a large number of pathway and disease terms are considered, multiple hypotheses tests are performed, which leads to a high overall Type-1 error even for a relatively stringent P-value cutoff. KOBAS 1.0 supports the FDR correction method QVALUE (39 ). In KOBAS 2.0, we add two more popular FDR correction methods: Benjamini-Hochberg (40 ) and Benjamini-Yekutieli (41 ).
The large and rapidly growing protein sequence databases provide a wealth of information for the identification of protein-coding transcript. We derive another three features from parsing the output of BLASTX (16 (link)) search (using the transcript as query, E-value cutoff 1e-10) against UniProt Reference Clusters (UniRef90) which was developed as a nonredundant protein database with a 90% sequence identity threshold (17 (link)). First, a true protein-coding transcript is likely to have more hits with known proteins than a non-coding transcript does. Thus we extract the NUMBER OF HITS as a feature. Second, for a true protein-coding transcript the hits are also likely to have higher quality; i.e. the HSPs (High-scoring Segment Pairs) overall tend to have lower E-value. Thus we define feature HIT SCORE as follows:
where Eij is the E-value of the j-th HSP in frame i, Si measures the average quality of the HSPs in frame i and HIT SCORE is the average of Si across three frames. The higher the HIT SCORE, the better the overall quality of the hits and the more likely the transcript is protein-coding. Thirdly, for a true protein-coding transcript most of the hits are likely to reside within one frame, whereas for a true non-coding transcript, even if it matches certain known protein sequence segments by chance, these chance hits are likely to scatter in any of the three frames. Thus, we define feature FRAME SCORE to measure the distribution of the HSPs among three reading frames:
The higher the FRAME SCORE, the more concentrated the hits are and the more likely the transcript is protein-coding.
We incorporate these six features into a support vector machine (SVM) machine learning classifier (18 ). Mapping the input features onto a high-dimensional feature space via a proper kernel function, SVM constructs a classification hyper-plane (maximum margin hyper-plane) to separate the transformed data (18 ). Known for its high accuracy and good performance, SVM is a widely used classification tool in bioinformatics analysis such as microarray-based cancer classification (19 (link),20 (link)), prediction of protein function (21 (link),22 (link)) and prediction of subcellular localization (23 (link),24 (link)). We employed the LIBSVM package (25 ) to train a SVM model using the standard radial basis function kernel (RBF kernel). The C and gamma parameters were determined by grid-search in the training dataset. We trained the SVM model using the same training data set as CONC used (13 (link)), containing 5610 protein-coding cDNAs and 2670 noncoding RNAs.
Most recents protocols related to «Microarray Analysis»
Example 1
As an initial proof of concept, a model system is developed using a microarray to demonstrate a working single-plex assay. The basic design validates the concept of the assay, and establishes a working assay prior to addressing issues related to the analysis of a more complicated biological sample. Conventional sequencing is used as a readout for this proof of concept.
A microarray is used as a proxy for a tissue section. The target sequences of the microarray are fully specified, so that the composition of the targets are known and can be varied systematically. Synthetic oligonucleotide templates are attached to a glass slide via a 5′ amino modification. Each slide has a single oligonucleotide template sequence, and the assays that are carried out may employ either ligation, or extension followed by ligation as this may be useful in determining certain polymorphisms.
Once the in situ part of the assay is complete, the reaction products are eluted and analyzed by qPCR to determined presence or absence of a product and estimate yield, and by conventional sequencing to determine the structure of the assay products. The single plex assays that are tested include appropriate positive and negative controls, and a single nucleotide variant (SNV) to check ability to discriminate single base variants.
Example 11
The present Example describes using activatable antibodies to detect expression and/or activation in tissue microarrays (TMAs). The anti-Jagged antibody 4D11 was used with a non-small cell lung cancer (NSCLC) TMA and a breast cancer (BC) TMA. Most of the NSCLC and BC patient tumor samples were positive for Jagged expression. The same NSCLC and BC TMAs were contacted with the activatable anti-Jagged antibody referred to herein as 5342-1204-4D11. 97% of NSCLC and 100% of BC patient tumor samples were positive for binding and activation of 5342-1204-4D11 activatable anti-Jagged antibody. Furthermore, more than 80% of the tumor samples were characterized by a high activation rate (++or +++) as shown in
Example 2
Our microarray data identified CH25H as a STAT1-regulated gene in AD conditions (
DNA from blood samples will be used for microarray-based genotyping of MDD candidate genes, genes of relevance for MDD (e.g., rs41271330, 5-HTTLPR, COMT, and BDNFval66met), drug metabolism (e.g., CYP2D6, CYP2C19, UGT1A1, ABCB1, ABCC1) and to compute polygenic risk scores in all participants after genome-wide genotyping in the future. DNA will also be used for epigenetic analysis, and circular extrachromosomal DNA, a form of decomposed free DNA [65 (link)], will be extracted and characterised. RNA will be extracted for gene transcription profiles using microarray or TAG-based methods (mRNA and microRNA).
DNA from blood samples will be used for microarray-based genotyping of MDD candidate genes, genes of relevance for MDD (e.g., rs41271330, 5-HTTLPR, COMT, and BDNFval66met), drug metabolism (e.g., CYP2D6, CYP2C19, UGT1A1, ABCB1, ABCC1) and to compute polygenic risk scores in all participants after genome-wide genotyping in the future. DNA will also be used for epigenetic analysis, and circular extrachromosomal DNA, a form of decomposed free DNA [65 (link)], will be extracted and characterised. RNA will be extracted for gene transcription profiles using microarray or TAG-based methods (mRNA and microRNA).
Gene analyses will be based on a priori models of genetic variations known to modulate pharmacotherapy and psychotherapy responses. The results will be used to calculate a polygenic risk score for diagnosis and treatment response and meta-analyses with established polygenic risk scores for MDD and those currently developed for anxiety and anxiety disorders, including treatment response [66 (link)].
Top products related to «Microarray Analysis»
More about "Microarray Analysis"
This high-throughput approach provides a comprehensive understanding of gene activity, enabling the investigation of complex biological processes and the identification of disease-related patterns.
By analyzing the expression profiles of multiple genes, Microarray Analysis facilitates the discovery of novel genetic markers, the elucidation of regulatory networks, and the development of personalized diagnostic and therapeutic strategies.
This powerful technology is commonly used in fields such as genomics, transcriptomics, and personalized medicine.
To ensure the accuracy and reproducibility of Microarray Analysis, researchers often utilize tools like the RNeasy Mini Kit, TRIzol reagent, and the Agilent 2100 Bioanalyzer for sample preparation and quality control.
The Feature Extraction software and the Agilent Microarray Scanner are also frequently employed to process and analyze the microarray data.
In addition to these tools, the Human Genome U133 Plus 2.0 Array and the MiRNeasy Mini Kit are widely used in Microarray Analysis for the comprehensive profiling of gene and microRNA expression, respectively.
PubCompare.ai, an AI-driven platform, optimizes Microarray Analysis by helping users find the best protocols from literature, pre-prints, and patents.
Leveraging AI-driven comparisons, PubCompare.ai enhances reproducibility and research accuracy, ensuring your Microarray Analysis is precise and realible.